ISSN 2148-4902
e-ISSN 2536-4553
 

Volume : 6 Issue : 2 Year : 2019

 
Helicobacter Pylori Treatment in Turkey: Current Status and Rational Treatment Options [North Clin Istanb]
North Clin Istanb. Ahead of Print: NCI-62558 | DOI: 10.14744/nci.2019.62558  

Helicobacter Pylori Treatment in Turkey: Current Status and Rational Treatment Options

Mustafa Kaplan1, Alpaslan Tanoglu1, Tolga Duzenli1, Nurdan Tozun2
1Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey.
2Department of Gastroenterology, Acibadem University, Istanbul, Turkey.

According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, many countries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1 gr b.i.d) for Helicobacter pylori treatment. At the beginning, eradication rates were above 90% in many countries, however, current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence, cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Therefore, each country/region needs to revise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori. The aim of this report was to review the current status of Helicobacter pylori treatment in Turkey and to give recommendations for rational therapeutic considerations for the eradication of bacterium.

Keywords: Helicobacter pylori; Turkey; eradication; proton pump inhibitors




Corresponding Author: Mustafa Kaplan


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar



 
©NCI 2019. Bu sitenin tüm hakları Istanbul Kuzey Klinikleri’ne aittir.